Drug
Semaglutide clinical trials
Also written Ozempic, Wegovy, NN9535 and NN9924.
- studies test it
- 426
- open now
- 151
- in phase 3
- 131
- first study started
- 2007
Keep track of what changes. Save the Semaglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Semaglutide
- 257
Development codes
Studies by the year they started
418 studies that test it; most in 2026 (65); 7 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2011 | 2 |
| 2012 | 4 |
| 2013 | 8 |
| 2014 | 18 |
| 2015 | 3 |
| 2016 | 12 |
| 2017 | 11 |
| 2018 | 12 |
| 2019 | 32 |
| 2020 | 12 |
| 2021 | 37 |
| 2022 | 44 |
| 2023 | 50 |
| 2024 | 56 |
| 2025 | 47 |
| 2026 | 65 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 96
- Phase 2
- 90
- Phase 3
- 131
- Phase 4
- 91
- No phase
- 30
What it is tested for
Each study’s main condition, where its own words name it.
- Obesity
- 94
Who runs them
Industry 202 · Other 224
Novo Nordisk A/S (182) · Yale University (6) · University of Colorado, Denver (6) · Mayo Clinic (5) · University Medical Centre Ljubljana (5) · General Committee of Teaching Hospitals and Institutes, Egypt (5) · Vanderbilt University Medical Center (4) · Zagazig University (3)
Often tested with
Tested in the same studies.
Cagrilintide (22) · Empagliflozin (11) · Tirzepatide (10) · Dapagliflozin (10) · Metformin (8) · Insulin icodec (7) · Finerenone (5) · Dulaglutide (4)
Studies
Open first, then newest update. How each study uses Semaglutide is read from its arms, and is right about nine times in ten.
Testing it · 426
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.RecruitingPhase 2/3McGill University Health Centre/Research Institute of the McGill University Health CentreNCT07891156Written as Semaglutide
- GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way ForwardNot yet recruitingPhase 4University of MinnesotaNCT06977438Written as Semaglutide
- Semaglutide for the Treatment of Cannabis Use DisorderNot yet recruitingPhase 2Massachusetts General HospitalNCT07879612Written as semaglutide
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide MedicationRecruitingPhase 1Novo Nordisk A/SNCT07855133Written as Semaglutide
- Short Term Effects of Semaglutide on Body Composition and PerformanceNot yet recruitingNot applicableMorten Hostrup, PhDNCT07874971Written as Semaglutide (SEMA)
- Long-Term Effects of Semaglutide on Body Composition and Performance in RunningNot yet recruitingNot applicableMorten Hostrup, PhDNCT07874932Written as Semaglutide (SEMA)
- FutureShape FamilyNot yet recruitingPhase 4Signe TorekovNCT07872904Written as Semaglutide (administered by PDS290 pen-injector)
- Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationPhase 4Baylor Research InstituteNCT07547878Written as Semaglutide
- Semaglutide for Helping Opioid RecoveryRecruitingPhase 2Brigham and Women's HospitalNCT06639464Written as Semaglutide
- Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric SurgeryNot yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859189Written as Semaglutide weekly injection
- Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric SurgeryNot yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859176Written as Semaglutide weekly injection
- Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or HigherNot yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859137Written as Semaglutide weekly injection
- Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight GainNot yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859163Written as Semaglutide weekly injection
- Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)Not yet recruitingPhase 4General Committee of Teaching Hospitals and Institutes, EgyptNCT07859150Written as Semaglutide weekly injection
- Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant AccessNot yet recruitingPhase 4Kristin ClemensNCT07858331Written as Semaglutide
- Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumRecruitingPhase 2GynOncTrialsNCT06073184Written as Wegovy
- Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 DiabetesRecruitingPhase 4Marzieh SalehiNCT06706284Written as Semaglutide Injectable Product
- The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectRecruitingPhase 3The George InstituteNCT06058585Written as Semaglutide
- Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial CancerNot yet recruitingPhase 2The Methodist Hospital Research InstituteNCT07820358Written as Semaglutide (Wegovy) weekly injection
- A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightRecruitingPhase 3Novo Nordisk A/SNCT07253285Written as Semaglutide
See all 426 studies that test Semaglutide →
Given in every arm · 26 — Semaglutide is usual care beside what is tested
- Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With AlbuminuriaNot yet recruitingNot applicablePeking University People's HospitalNCT07849348Written as Semaglutide
- Free Fatty Acid Effects In Type 2 DiabetesEnrolling by invitationNot applicableUniversity of UlsterNCT07677995Written as Semaglutide 0.25 mg
- Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialRecruitingPhase 2City of Hope Medical CenterNCT07202247Written as Semaglutide
- Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese AdultsNot yet recruitingPhase 2Lumos PharmaNCT07754045Written as Semagludtide
- Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With ObesityRecruitingNot applicableWashington University School of MedicineNCT07091500Written as Semaglutide
- SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.Not yet recruitingPhase 2Ministry of Health, Saudi ArabiaNCT07614412Written as Semaglutide (Ozempic®)
- Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 DiabetesNot yet recruitingNot applicableEighth Affiliated Hospital, Sun Yat-sen UniversityNCT07599046Written as Semaglutide (1 Mg Dose)
- Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DMNot yet recruitingNot applicableShanghai Jiao Tong University School of MedicineNCT07570810Written as Semaglutide
- Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.Not yet recruitingPhase 2BiophytisNCT07411378Written as Semaglutide
- Optimizing Albuminuria Treatment in CKD With Finerenone and SemaglutideCompletedPhase 2University Medical Center GroningenNCT07819227Written as Semaglutide 14 MG [Rybelsus]
- Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight LossActive, not recruitingPhase 2Veru Inc.NCT07446998Written as Semaglutide (Wegovy) weekly injection
- A Study of CS060380 Tablets in Patients With MASH and ObesityActive, not recruitingPhase 2Cascade Pharmaceuticals, IncNCT07466017Written as semaglutide
- A Trial to Evaluate Safety, Feasibility and Efficacy of Endoscopic Duodenal PEF TherapyCompletedNot applicableAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)NCT05984238Written as Semaglutide, 1.0 mg/mL
- MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) TrialActive, not recruitingPhase 2EccogeneNCT07505303Written as Semaglutide
- A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body WeightCompletedPhase 1Novo Nordisk A/SNCT06289504Written as Semaglutide
- Tailoring Obesity Treatment TrialWithdrawnPhase 2/3Esbjerg Hospital - University Hospital of Southern DenmarkNCT06619015Written as Semaglutide Pen Injector
- A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DMWithdrawnPhase 2Halia Therapeutics, Inc.NCT07172867Written as Semaglutide 1 mg
- A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose WeightCompletedPhase 3Novo Nordisk A/SNCT05813925Written as Semaglutide
- A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IVCompletedPhase 1Novo Nordisk A/SNCT06642584Written as Semaglutide B
- Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight MgmtCompletedPhase 2Veru Inc.NCT06282458Written as Semaglutide
Showing 20 of 26.
As the comparator · 65 — what is tested is compared with Semaglutide
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusRecruitingPhase 3AstraZenecaNCT07662213Written as Semaglutide
- A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or ObesityRecruitingPhase 3PfizerNCT07845500Written as Semaglutide
- A Study of BGM0504 in Early T2DM With ObesityRecruitingPhase 3BrightGene Bio-Medical Technology Co., Ltd.NCT07743983Written as semaglutide
- Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 DiabetesNot yet recruitingPhase 3AmgenNCT07866066Written as Semaglutide
- A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesRecruitingPhase 2Novo Nordisk A/SNCT07668388Written as Semaglutide
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightRecruitingPhase 3Novo Nordisk A/SNCT07564414Written as Semaglutide
- A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideRecruitingPhase 3Novo Nordisk A/SNCT07668414Written as Semaglutide
- Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)RecruitingPhase 3The United Bio-Technology (Hengqin) Co., Ltd.NCT07653477Written as Semaglutide Injection
- A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesRecruitingPhase 2Novo Nordisk A/SNCT07415954Written as Semaglutide
- A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)Not yet recruitingPhase 2Beijing QL Biopharmaceutical Co.,LtdNCT07812597Written as semaglutide
- Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes MellitusRecruitingPhase 2Shanghai Minwei Biotechnology Co., LtdNCT07801820Written as Semaglutide Tablets
- A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityRecruitingPhase 1Novo Nordisk A/SNCT07767175Written as Semaglutide
- Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese ParticipantsRecruitingPhase 1Terrestrial Bio, Inc.NCT07673900Written as semaglutide SC
- Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthRecruitingPhase 2/3University of Colorado, DenverNCT06975111Written as semaglutide
- Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With SemaglutideNot yet recruitingNot applicableTianjin Medical UniversityNCT07713992Written as Semaglutide (1 Mg Dose)
- BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesNot yet recruitingPhase 3Carnot LaboratoriesNCT07628985Written as Semaglutide
- BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityNot yet recruitingPhase 3Carnot LaboratoriesNCT07622810Written as Semaglutide
- Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 DiabetesNot yet recruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07487103Written as Rybelsus
- Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1Not yet recruitingPhase 4William Marsh Rice UniversityNCT07554417Written as Semaglutide
- The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and ObesityRecruitingPhase 1CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.NCT06830343Written as Wegovy ®
Showing 20 of 65.
Codes
What other systems call Semaglutide · ClinicalTrials.gg INT006888
- MeSH (NLM) D000099194SemaglutideConfirmed NLM, Wikidata
- UNII (FDA) 53AXN4NNHXSEMAGLUTIDEConfirmed FDA, NLM, Wikidata
- RxNorm 1991302Confirmed FDA, Wikidata
- Wikidata Q27261089semaglutideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152328SemaglutideOne source FDA
- DrugBank DB13928One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000099194 | Semaglutide | Confirmed NLM, Wikidata |
| UNII (FDA) | 53AXN4NNHX | SEMAGLUTIDE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1991302 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27261089 | semaglutide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152328 | Semaglutide | One source FDA |
| DrugBank | DB13928 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.